Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva is viewed favorably because lanifibranor has already shown a large Phase 2 histology signal, including nearly 19 points of placebo-adjusted fibrosis benefit and a strong composite response, giving NATiV3 a meaningful statistical cushion even with missing biopsies and placebo drift. The Phase 3 trial enrolled 1,009 F2/F3 MASH patients, completed its last patient visit on September 2, and is guided to topline data in Q4 2026, while management and analysts expect the direct antifibrotic mechanism to differentiate it from Rezdiffra’s more modest, indirect effect. The outlook is further supported by manageable safety to date, cash of €233.9M at June 30, 2026 with runway into 2Q 2027, and a large addressable market that could translate into multibillion-euro peak sales if the 72-week readout confirms efficacy.

Inventiva is viewed negatively because its key clinical evidence remains vulnerable to translation risk: NATIVE used an older SAF score, included nearly 24% F0–F1 patients, and FASST in systemic sclerosis missed its primary endpoint and was stopped in February 2019. Safety and tolerability are also problematic, with diarrhea, nausea, edema, anemia, aminotransferase elevations, and mean weight gain of 2.4–2.7 kg, which can limit long-term adherence in a disease where weight loss is expected. Fundamentally, the company faces commercialization and financing pressure as higher edema burden may weaken competitiveness in F2 and nondiabetic MASH patients versus existing options and emerging FGF21 agonists, while dilutive financing remains a stated risk.